Kewaunee Scientific ( (KEQU) ) has released its Q4 earnings. Here is a breakdown of the information Kewaunee Scientific presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Kewaunee Scientific Corporation is a global leader in the design, manufacture, and installation of laboratory, healthcare, and technical furniture products, with a strong presence in both domestic and international markets.
Kewaunee Scientific reported a robust performance for the fourth quarter and fiscal year 2025, marked by significant increases in sales and adjusted earnings, despite challenges in the international segment and costs associated with the acquisition of Nu Aire, Inc.
The company achieved a 36.1% increase in fourth-quarter sales, reaching $77.1 million, and a notable rise in adjusted pre-tax earnings by 56.7% compared to the previous year. The acquisition of Nu Aire contributed to the domestic segment’s growth, while international sales faced delays. For the full fiscal year, sales rose by 18%, with adjusted net earnings increasing by 29.8%.
Despite a decrease in cash reserves due to the Nu Aire acquisition, Kewaunee maintained a healthy order backlog and improved working capital. The company’s strategic focus on product portfolio investments and strengthening dealer relationships continues to drive its performance.
Looking ahead, Kewaunee Scientific remains committed to growth through both organic and inorganic means, leveraging its strong market position and strategic acquisitions to deliver value to its stakeholders in a challenging economic environment.